A Healthy Lifestyle May Help Prevent Liver-related Deaths
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver...
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver...
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver...
Preliminary data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of...
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver...
Data from a new study presented this week at The Liver Meeting® – held by the American Association for the Study of Liver...
Data from a new study presented this week at The Liver Meeting Digital Experience® – held by the American Association for the...
Nobuhisa Akamatsu, Kiyoshi Hasegawa, Kayo Nojiri, Kaori Muto, Junichi Shimizu, Etsuko Soeda, Naoki Kawagishi, Shigeru Marubashi, Koichi Mizuta, Toshimi Kaido, Akinobu Taketomi, Hideki Ohdan, Shinji Uemoto, Norihiro Kokudo – 1 June 2022
Tolga Gidener, Ross A. Dierkhising, Kristin C. Mara, Terry M. Therneau, Sudhakar K. Venkatesh, Richard L. Ehman, Meng Yin, Alina M. Allen – 31 May 2022
Margit Mahlapuu, Mara Caputo, Ying Xia, Emmelie Cansby – 30 May 2022 – Nonalcoholic fatty liver disease (NAFLD) is defined by excessive accumulation of lipid droplets within hepatocytes. The STE20‐type kinases comprising the germinal center kinase III (GCKIII) subfamily – MST3, MST4, and STK25 – decorate intrahepatocellular lipid droplets and have recently emerged as critical regulators of the initiation and progression of NAFLD.
Tsuyoshi Fukumoto, Tatsuya Minami, Makoto Moriyama, Tomoharu Yamada, Taijiro Wake, Mizuki Nishibatake Kinoshita, Naoto Fujiwara, Ryo Nakagomi, Takuma Nakatsuka, Masaya Sato, Kenichiro Enooku, Hayato Nakagawa, Mitsuhiro Fujishiro, Shuichiro Shiina, Kazuhiko Koike, Ryosuke Tateishi – 30 May 2022 – The prognostic impact of direct‐acting antivirals (DAAs) on patients with hepatitis C‐related hepatocellular carcinoma (C‐HCC) is still unclear. This study aimed to evaluate the prognosis of C‐HCC in the DAA era.